RT Journal Article SR Electronic T1 Carboplatin plus Either Docetaxel or Paclitaxel for Japanese Patients with Advanced Non-small Cell Lung Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 4631 OP 4637 VO 33 IS 10 A1 MASAAKI KAWAHARA A1 SHINJI ATAGI A1 KIYOSHI KOMUTA A1 HIROSHIGE YOSHIOKA A1 MASAYUKI KAWASAKI A1 YUKA FUJITA A1 TOSHIRO YONEI A1 FUMITAKA OGUSHI A1 KAORU KUBOTA A1 NAOYUKI NOGAMI A1 MICHIKO TSUCHIYA A1 KAZUHIKO SHIBATA A1 YOSHIO TOMIZAWA A1 KOICHI MINATO A1 KAZUYA FUKUOKA A1 KAZUHIRO ASAMI A1 TAKEHARU YAMANAKA A1 THE JAPAN MULTINATIONAL TRIAL ORGANIZATION YR 2013 UL http://ar.iiarjournals.org/content/33/10/4631.abstract AB Aim: Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naïve patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m2) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m2) plus carboplatin (same dose), on day 1 every 21 days. The primary end-point was progression-free survival (PFS). Results: A total of 90 patients were enrolled. Overall response rate, median PFS and median survival time in the docetaxel-plus-carboplatin group and the paclitaxel-plus-carboplatin group were 23% vs. 33%, 4.8 months vs. 5.1 months, and 17.6 months vs. 15.6 months, respectively. The docetaxel-plus-carboplatin group had a higher incidence of grade 3 or 4 neutropenia (88% vs. 60%). Conclusion: Both regimens were similarly effective in Japanese patients with advanced NSCLC.